1021. Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • Repeat Endocarditis In PWID ID Week 2018.pdf (109.8 kB)
  • Background: Injection drug use (IDU) is a major risk factor for infective endocarditis (IE). Rates of IE have recently increased in the US concurrent with the opioid crisis. Although IDU-related IE is well described, few data exist on repeat IE (rIE) in persons who inject drugs (PWID).

    Methods: Patients ≥ 18 years old seen at Wake Forest Baptist Medical Center from 2004-2017 with an ICD-9 or -10 diagnosis of IE who met Duke criteria for IE and who self-reported IDU in the 3 months prior to admission were identified. The subset of PWID who developed rIE, defined as another episode of IE at least 10 weeks after the diagnosis of the 1st episode, were then reviewed.

    Results: Of the 94 PWID with IE, 22 (23.4%) experienced rIE (19 re-infections, 3 relapses). All patients were Caucasian, 50% were male, and 68.2% lived in rural areas; the median age was 30. All 22 patients resumed IDU after their 1st episode of IE. The mean duration from completion of antibiotics for the prior IE episode to admission with rIE was 257.5 days; the episode of rIE occurred within 1 year in 17 patients (77.3%). On repeat admission, those with rIE had a Pitt bacteremia score of 3.0 and an APACHE II score of 13.1. Fever and bacteremia persisted for an average of 5.6d and 2.6d, respectively. S aureus was the cause of rIE in 54.5% of patients and the tricuspid valve (TV) was involved in 77.3% of cases. Valve surgery occurred in 22.7% of patients. Mean length of stay was 25.3d and mean duration of antibiotic therapy was 32.1d. Seven patients (31.8%) died during the rIE hospitalization and another died within 12 months after discharge resulting in a 1-year mortality of 36.3%. Compared to their 1st episode of IE, rIE patients had higher admission Pitt bacteremia (3.0 vs 1.5, p=0.07) and APACHE II scores (13.1 vs 9.5, p=0.18) , fewer S aureus infections (54.5% vs 95.4%, p=0.01), similar TV involvement (77.3% vs 72.7%, p=1), and less frequent surgery (22.7% vs 59.1%, p=0.06).

    Conclusion: rIE is common in PWID with most episodes occurring within 1 year of the initial episode. Reinfection is more frequent than relapse. The microbiology of rIE is more varied than 1st episode IE in PWID with S aureus being less frequently isolated. Illness severity is high, hospitalizations are prolonged, and 1-year mortality is significant. More effective strategies for preventing rIE in PWID are needed.

    Glen Huang, DO1, Erin Barnes, MD2 and James Peacock, MD2, (1)Internal Medicince, Wake Forest Baptist Med Ctr (WFBMC), Winston Salem, NC, (2)Infectious Diseases, Wake Forest Baptist Med Ctr (WFBMC), Winston Salem, NC

    Disclosures:

    G. Huang, None

    E. Barnes, None

    J. Peacock, Pfizer: Shareholder , Owns common stock in Pfizer which was inherited and held in a trust .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.